Last reviewed · How we verify
Baritinib
Baritinib is a Small molecule drug developed by De-zhi Kang. It is currently in Phase 2 development.
Baritinib is being studied as a potential treatment for various conditions, including intracerebral hemorrhage, acute lung injury, spondyloarthritis, alopecia areata, and intracerebral hemorrhage-related respiratory injury. The exact mechanism of action of Baritinib is not specified, but it is classified as a Janus Kinase inhibitor, which suggests it works by inhibiting the Janus Kinase enzyme.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Baritinib |
|---|---|
| Sponsor | De-zhi Kang |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Baricitinib for Respiratory Injury in Patients With Intracerebral Hemorrhage (PHASE2)
- Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
- Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Baritinib CI brief — competitive landscape report
- Baritinib updates RSS · CI watch RSS
- De-zhi Kang portfolio CI
Frequently asked questions about Baritinib
What is Baritinib?
Who makes Baritinib?
What development phase is Baritinib in?
Related
- Manufacturer: De-zhi Kang — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing